Black Diamond (BDTX) CMO Sergey Yurasov Receives Equity Award

What Happened

• Sergey Yurasov, Chief Medical Officer of Black Diamond Therapeutics (BDTX), was granted an equity award for 250,000 shares/units on January 21, 2026. The Form 4 reports the acquisition price as $0.00 and labels the transaction as a derivative award (code A).

Key Details

• Transaction date: 2026-01-21; filing date: 2026-01-23 (filed within the typical 2-business-day Section 16 reporting window).
• Amount granted: 250,000 shares/units; reported acquisition price: $0.00.
• Post-transaction holdings: Not specified in the provided filing excerpt.
• Footnote (vesting): 25% of the shares vest on January 21, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service.
• Transaction type: Award/grant of a derivative security (not an open-market purchase or sale).

Context

• This appears to be a time-based equity compensation award (options or RSUs) intended for retention/compensation. The $0.00 acquisition price on the Form 4 reflects the grant reporting; any exercise price, tax withholding, or future sale would be reported in later filings if applicable. Equity awards are common and do not by themselves indicate insider buying or selling sentiment.